Literature DB >> 7691514

Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part II).

J P Herrman1, W R Hermans, J Vos, P W Serruys.   

Abstract

Part I of this article reviewed the results of studies investigating the effectiveness of antithrombotic, antiplatelet, antiproliferative, anti-inflammatory, calcium channel blocker and lipid-lowering drugs in preventing or reducing restenosis after angioplasty. However, despite 15 years of clinical experience and research in the field of restenosis prevention, this has not yet resulted in the revelation of unequivocal beneficial effects of any particular drug. Other newer approaches likely to receive more attention in the future include antibodies to growth factors, gene transfer therapy and antisense oligonucleotides. Whether there is a feasible monotherapy, whether we have to focus on a drug combination, or whether we are only searching for 'the Holy Grail' remain to be answered.

Entities:  

Mesh:

Year:  1993        PMID: 7691514     DOI: 10.2165/00003495-199346020-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  164 in total

1.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF.

Authors:  G A Ferns; E W Raines; K H Sprugel; A S Motani; M A Reidy; R Ross
Journal:  Science       Date:  1991-09-06       Impact factor: 47.728

2.  Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty.

Authors:  S Okamoto; M Inden; M Setsuda; T Konishi; T Nakano
Journal:  Am Heart J       Date:  1992-06       Impact factor: 4.749

3.  Pharmacological therapy after coronary angioplasty. Early experience with low molecular weight heparin for prophylaxis of reocclusion.

Authors:  T Schmidt; U Tebbe; J Schrader; S Brune; H Kreuzer
Journal:  Klin Wochenschr       Date:  1990-03-05

4.  Comparative results of percutaneous transluminal coronary angioplasty in patients with dynamic versus fixed coronary stenosis.

Authors:  M E Bertrand; J M LaBlanche; F A Thieuleux; J L Fourrier; G Traisnel; P Asseman
Journal:  J Am Coll Cardiol       Date:  1986-09       Impact factor: 24.094

Review 5.  Platelet inhibitor agents in cardiovascular disease: an update.

Authors:  B Stein; V Fuster; D H Israel; M Cohen; L Badimon; J J Badimon; J H Chesebro
Journal:  J Am Coll Cardiol       Date:  1989-10       Impact factor: 24.094

6.  Fish oil supplements for prevention of restenosis after coronary angioplasty.

Authors:  U Kaul; S Sanghvi; V K Bahl; V Dev; H S Wasir
Journal:  Int J Cardiol       Date:  1992-04       Impact factor: 4.164

7.  Restenosis after directional coronary atherectomy: differences between primary atheromatous and restenosis lesions and influence of subintimal tissue resection.

Authors:  K N Garratt; D R Holmes; M R Bell; J F Bresnahan; U P Kaufmann; R E Vlietstra; W D Edwards
Journal:  J Am Coll Cardiol       Date:  1990-12       Impact factor: 24.094

8.  Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty.

Authors:  G E Austin; N B Ratliff; J Hollman; S Tabei; D F Phillips
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

9.  Rationale for use of glucocorticoids in modification of restenosis after percutaneous transluminal coronary angioplasty.

Authors:  R G Macdonald; R S Panush; C J Pepine
Journal:  Am J Cardiol       Date:  1987-07-31       Impact factor: 2.778

10.  Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin.

Authors:  A B Buchwald; D Sandrock; C Unterberg; M Ebbecke; K Nebendahl; S Lüders; D L Munz; V Wiegand
Journal:  J Am Coll Cardiol       Date:  1993-01       Impact factor: 24.094

View more
  3 in total

Review 1.  Mechanisms of restenosis.

Authors:  W Casscells; D Engler; J T Willerson
Journal:  Tex Heart Inst J       Date:  1994

Review 2.  Abciximab. An updated review of its use in ischaemic heart disease.

Authors:  R H Foster; L R Wiseman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 3.  Thrombin and antithrombotic therapy in interventional cardiology.

Authors:  J P Herrman; P W Serruys
Journal:  Tex Heart Inst J       Date:  1994
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.